JP Morgan Chase’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-55,000
Closed -$3.4M 7821
2026
Q1
$3.4M Sell
55,000
-40,000
-42% -$2.79M ﹤0.01% 3674
2025
Q4
$6.31M Buy
+95,000
New +$6.14M ﹤0.01% 3100
2025
Q1
Sell
-13,700
Closed -$1.07M 7394
2024
Q4
$1.07M Hold
13,700
﹤0.01% 4591
2024
Q3
$918K Hold
13,700
﹤0.01% 4519
2024
Q2
$1.55M Sell
13,700
-7,200
-34% -$910K ﹤0.01% 3977
2024
Q1
$2.9M Sell
20,900
-104,900
-83% -$13.2M ﹤0.01% 3542
2023
Q4
$15.6M Buy
125,800
+125,000
+15,625% +$12.8M ﹤0.01% 2055
2023
Q3
$74.6K Buy
+800
New +$90.2K ﹤0.01% 5647
2023
Q1
Sell
-95,000
Closed -$10.8M 6812
2022
Q4
$10.8M Buy
+95,000
New +$10.4M ﹤0.01% 2184
2022
Q1
Sell
-290,800
Closed -$39M 6682
2021
Q4
$39M Buy
+290,800
New +$41.8M ﹤0.01% 1342
2021
Q1
Sell
-36,400
Closed -$3.36M 6119
2020
Q4
$3.36M Buy
+36,400
New +$3.25M ﹤0.01% 3112
2019
Q1
Sell
-31,600
Closed -$946K 5821
2018
Q4
$946K Buy
+31,600
New +$1M ﹤0.01% 3778
2015
Q2
Sell
-32,000
Closed -$499K 4046
2015
Q1
$499K Buy
+32,000
New +$483K ﹤0.01% 3533

Other funds holding DXCM

JP Morgan Chase's DXCM Position: Q2 2026 in Review

JP Morgan Chase reduced its DexCom (DXCM) stake by 45% in Q2 2026, selling an estimated $178M and leaving 3,325,095 shares worth $233M. The position accounts for 0.01% of the portfolio, ranked #696.

JP Morgan Chase first reported a position in DXCM in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.64B in Q3 2021. 974 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • JP Morgan Chase held 3,325,095 shares of DexCom worth $233M as of Q2 2026.
  • JP Morgan Chase sold 2,674,375 DexCom shares in Q2 2026, an estimated $178M.
  • DexCom made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #696 holding.
  • JP Morgan Chase first reported a position in DexCom in Q2 2013 and has held it in 51 quarters since.
  • JP Morgan Chase's DexCom position peaked at $1.64B in Q3 2021.
  • 974 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.